Home UPDATE 2-Celgene to stop blood cancer trial due to high death rates
 

Keywords :   


UPDATE 2-Celgene to stop blood cancer trial due to high death rates

2013-07-18 23:40:32| Biotech - Topix.net

Celgene Corp said it will stop a late-stage trial of its blood cancer drug, Revlimid, after it observed a higher number of deaths in elderly leukemia patients taking the drug compared with those on another treatment.

Tags: high due rates update

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
04.11Tropical Depression Eighteen Graphics
04.11Tropical Depression Eighteen Public Advisory Number 4A
04.11Remnants of Patty Graphics
04.11Atlantic Tropical Weather Outlook
04.11Eastern North Pacific Tropical Weather Outlook
04.11Paper Excellence Group Rebrands as Domtar
04.11Registration Open for 2025 Waterborne Symposium
04.11ROSS Ribbon Blenders Provide Safe, Efficient Bulk Blending
More »